AU2018345625A1 - Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis - Google Patents
Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis Download PDFInfo
- Publication number
- AU2018345625A1 AU2018345625A1 AU2018345625A AU2018345625A AU2018345625A1 AU 2018345625 A1 AU2018345625 A1 AU 2018345625A1 AU 2018345625 A AU2018345625 A AU 2018345625A AU 2018345625 A AU2018345625 A AU 2018345625A AU 2018345625 A1 AU2018345625 A1 AU 2018345625A1
- Authority
- AU
- Australia
- Prior art keywords
- week
- antibody
- patient
- binding fragment
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568060P | 2017-10-04 | 2017-10-04 | |
| US62/568,060 | 2017-10-04 | ||
| US201862652615P | 2018-04-04 | 2018-04-04 | |
| US62/652,615 | 2018-04-04 | ||
| PCT/US2018/053976 WO2019070714A1 (en) | 2017-10-04 | 2018-10-02 | ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018345625A1 true AU2018345625A1 (en) | 2020-04-16 |
Family
ID=64051671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018345625A Abandoned AU2018345625A1 (en) | 2017-10-04 | 2018-10-02 | Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200262897A1 (https=) |
| EP (2) | EP4424324A3 (https=) |
| JP (2) | JP2020536097A (https=) |
| KR (1) | KR20200059279A (https=) |
| CN (1) | CN111278857A (https=) |
| AU (1) | AU2018345625A1 (https=) |
| BR (1) | BR112020006692A2 (https=) |
| CA (1) | CA3078362A1 (https=) |
| CO (1) | CO2020004831A2 (https=) |
| MX (1) | MX2020003619A (https=) |
| WO (1) | WO2019070714A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| US20210215714A1 (en) * | 2018-05-25 | 2021-07-15 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
| KR20210104071A (ko) | 2018-12-17 | 2021-08-24 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 표적 투약 |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025257877A1 (ja) * | 2024-06-10 | 2025-12-18 | 株式会社I’mbesideyou | 情報処理システム及び情報処理方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| LT2894165T (lt) * | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| NZ789212A (en) * | 2016-06-17 | 2026-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2018
- 2018-10-02 WO PCT/US2018/053976 patent/WO2019070714A1/en not_active Ceased
- 2018-10-02 AU AU2018345625A patent/AU2018345625A1/en not_active Abandoned
- 2018-10-02 BR BR112020006692-3A patent/BR112020006692A2/pt not_active IP Right Cessation
- 2018-10-02 JP JP2020519138A patent/JP2020536097A/ja active Pending
- 2018-10-02 EP EP24174774.0A patent/EP4424324A3/en active Pending
- 2018-10-02 MX MX2020003619A patent/MX2020003619A/es unknown
- 2018-10-02 EP EP18796165.1A patent/EP3692064A1/en not_active Withdrawn
- 2018-10-02 US US16/651,520 patent/US20200262897A1/en not_active Abandoned
- 2018-10-02 CA CA3078362A patent/CA3078362A1/en not_active Abandoned
- 2018-10-02 CN CN201880065034.5A patent/CN111278857A/zh active Pending
- 2018-10-02 KR KR1020207012177A patent/KR20200059279A/ko not_active Withdrawn
-
2020
- 2020-04-20 CO CONC2020/0004831A patent/CO2020004831A2/es unknown
-
2023
- 2023-02-28 US US18/115,226 patent/US20240025975A1/en active Pending
- 2023-05-31 JP JP2023089908A patent/JP2023101717A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020536097A (ja) | 2020-12-10 |
| US20240025975A1 (en) | 2024-01-25 |
| EP3692064A1 (en) | 2020-08-12 |
| EP4424324A2 (en) | 2024-09-04 |
| KR20200059279A (ko) | 2020-05-28 |
| MX2020003619A (es) | 2020-10-28 |
| EP4424324A3 (en) | 2024-11-06 |
| CN111278857A (zh) | 2020-06-12 |
| BR112020006692A2 (pt) | 2020-10-06 |
| CO2020004831A2 (es) | 2020-05-29 |
| JP2023101717A (ja) | 2023-07-21 |
| CA3078362A1 (en) | 2019-04-11 |
| US20200262897A1 (en) | 2020-08-20 |
| WO2019070714A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240025975A1 (en) | Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| JP7518764B2 (ja) | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 | |
| JP7577542B2 (ja) | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 | |
| JP6306588B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| AU2024266818B2 (en) | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) | |
| CN112996561A (zh) | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 | |
| JP7589045B2 (ja) | リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 | |
| JP2026026191A (ja) | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 | |
| WO2022264101A1 (en) | Method of treating an autoimmune hematological disorder | |
| JP2020517605A (ja) | 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性 | |
| US20230009657A1 (en) | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists | |
| RU2822664C2 (ru) | ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС) | |
| JP6923594B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| HK40110798A (en) | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody | |
| WO2025166118A1 (en) | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) | |
| JP2023507852A (ja) | 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |